Implementation of prenatal and maternal therapy is crucial to, respectively, prevent congenital disease morbidity and mortality and ensure gestational health. The first step is an in vitro comparison of drug delivery system uptake and subsequent Green Fluorescent Protein (GFP) messenger RNA (mRNA) expression. This report investigates Onpattro® (Patisiran), Spikevax (Moderna), Comirnaty (Pfizer/BioNTech) lipid nanoparticle formulations and compares them statistically to a lipofectamine control. The placental trophoblast HTR-8/SVneo cell line model is cultured and primarily exposed to 1 μg/mL of each formulation over a period of 48 hours. Corrected Total Cell Fluorescence (CTCF) and percentage of cells fluorescing GFP above the mean signal highlight that expression is affected by the library of LNP used. In particular, the ionizable lipid is suspected to be the main factor affecting uptake and expression: in the future, the Spikevax (Moderna) ionizable lipid SM-102 will be further investigated.

• This report represents the work of one or more WPI undergraduate students submitted to the faculty as evidence of completion of a degree requirement. WPI routinely publishes these reports on its website without editorial or peer review.

Creator

• Benazzi, Michela
• Shea, Matthew

Publisher

• Worcester Polytechnic Institute

Identifier

• E-project-042723-110542
• 105966

Advisor

• Bailey, Christina M.

Year

• 2023

Date created

• 2023-04-27

Resource type

• Major Qualifying Project

Major

• Chemical Engineering

Source

• E-project-042723-110542

Rights statement

• In Copyright

Last modified

• 2023-06-21